title: [Regional treatment of esophageal liver metastasis by intra-arterial low-dose 5-FU therapy].
abstract: The prognosis of esophageal liver metastasis remains poor because of the high incidence of synchronous metastasis in other area and insufficient response to systemic chemotherapy. We assessed loco-regional anticancer potential of intra-arterial 5-FU chemotherapy for esophageal liver metastasis aimed at combination with systemic chemotherapy, radiotherapy and ablation therapy as a multidisciplinary treatment. Six patients of esophageal cancer with liver metastasis and without extra-hepatic metastasis were enrolled. Intra-aortic chemotherapy consisted of 5-FU (250 mg/body) in a one-shot infusion or a continuous infusion for 7 days with 2-week intervals until failure. The responses of liver metastasis were 2 cases of CR, 3 of PR and 1 of SD. The response rate and the local control rate were 83% and 100%, respectively. The maximum time to progression was 53 months. Grade 3/4 toxicity was not observed. Two cases had catheter failure and the treatment was interrupted. Liver metastases were controlled well until death in all cases except one. Low-dose intra-aortic 5-FU chemotherapy provided a good regional response and a combination with systemic chemotherapy may prolong survival for the patients of liver metastasis of esophageal cancer.
authors.affiliation: Dept. of Frontier Surgery, Chiba University Graduate School of Medicine.
authors.forename: Kiyohiko
authors.initials: K
authors.lastname: Shuto
authors.forename: Gaku
authors.initials: G
authors.lastname: Ohira
authors.forename: Tsuguaki
authors.initials: T
authors.lastname: Kono
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Natsume
authors.forename: Takayuki
authors.initials: T
authors.lastname: Tohma
authors.forename: Asami
authors.initials: A
authors.lastname: Sato
authors.forename: Takumi
authors.initials: T
authors.lastname: Ota
authors.forename: Hiroshige
authors.initials: H
authors.lastname: Saito
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Akutsu
authors.forename: Masaya
authors.initials: M
authors.lastname: Uesato
authors.forename: Hisahiro
authors.initials: H
authors.lastname: Matsubara
authors.forename: Shinichi
authors.initials: S
authors.lastname: Okazumi
authors.forename: Takehito
authors.initials: T
authors.lastname: Kaiho
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D004938:Esophageal Neoplasms / Q000473:pathology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged
chemical_list: D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil